New drugs using heart organ chip data have been approved for clinical trials in China. At the end of May 2023, the website of the State Food and Drug Administration showed that Jiangsu Hengrui Medicine HRS-1893 tablets were approved for clinical trials. It is understood that HRS-1893 inhibits excessive myocardial contraction through a special mechanism and is intended for the treatment of hypertrophic cardiomyopathy and heart failure caused by myocardial hypertrophy. It is understood that the in vitro screening of the study was carried out by the Suzhou Institute of Medical Devices, Southeast University, entrusted by Jiangsu Hengrui Medicine subsidiary Jiangsu Hengrui Medicine Co., Ltd. It is reported that the in vitro screening work of this study is based on organ chip technology to evaluate the impact of drugs on the contraction amplitude and calcium transient peak of heart organ chips. A total of 9 batches of over 100 compounds have been screened. This collaboration efficiently and accurately screened the in vitro activity and drug selectivity of compounds, identifying candidate molecules for future in vivo pharmacological experiments, "said Feng Jun, Deputy General Manager of Shanghai Hengrui R&D Center. It is understood that Jiangsu Hengrui Medicine is an innovative international pharmaceutical enterprise focusing on R&D, production and promotion of high-quality drugs, and one of the most innovative pharmaceutical leading enterprises in China. The human organ chip is an organ microphysiological system constructed in vitro through the cross integration of cutting-edge technologies such as stem cells, biomaterials, and nanoprocessing. It can simulate the main structural and functional characteristics of different tissues and organs in the human body, as well as complex inter organ connections, to predict the human body's response to drugs or external stimuli. It is understood that the human organ chip project of Southeast University Suzhou Medical Device Research Institute, with the support of Southeast University, Jiangsu Industrial Technology Research Institute and Suzhou High tech Zone, will be transformed into Jiangsu Aiweide Biotechnology Co., Ltd. (hereinafter referred to as "Aiweide Biotechnology") on November 11, 2021. Aiweide Biology received attention at the beginning of its establishment, and completed nearly 100 million yuan of pre A round of financing led by Fosun Pharma within half a year. According to reports, Aiweide Biology is mainly engaged in the research, development and application of human organ chips and supporting equipment. It has a series of core key technologies such as organ chip design/processing, extracellular scaffold material preparation, automatic cultivation of Organoid, multimodal imaging and artificial intelligence data analysis. It has complete organ chip design, development and production capabilities, and design and manufacturing capabilities of automatic equipment and software, As well as Organoid culture reagent production and technical service capabilities, it is a Organoid and organ chip company that can provide a full range of solutions. The tumor, heart, skin and other organ chips independently developed by Aiweide Biology, as well as supporting cultivation and detection kits, automated cultivation and high content detection and analysis instruments, AI software systems, biomaterials and other products, have been sold and applied in pharmaceutical companies, hospitals, and research institutions such as Hengrui. In the future, the organ chip team of the Suzhou Institute of Medical Devices, Southeast University, the National Key Laboratory of Digital Medical Engineering and Jiangsu Aiweide Biotechnology Co., Ltd. will continue to make breakthroughs in technology, develop highly simulated in vitro humanized physiological and pathological models, and help drug creation and accurate diagnosis and treatment. (Author: Wu Xiaoyue)